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Formation of Neuronal Intranuclear Inclusions
Underlies the Neurological Dysfunction in Mice
Transgenic for the HD Mutation
Stephen W. Davies,* Mark Turmaine,* never be seen. Juvenile symptoms also include myoclo-
nus, epileptic seizures, and tremor. Patients have a veryBarbara A. Cozens,* Marian DiFiglia,²
high calorific intake but paradoxically generally loseAlan H. Sharp,³ Christopher A. Ross,³
weight. Currently, HD has no effective therapy.Eberhard Scherzinger,§ Erich E. Wanker,§
The most thorough study of the neuropathology ofLaura Mangiarini,‖ and Gillian P. Bates‖
HD classified the neuropathological changes into five*Department of Anatomy and Developmental Biology
grades: grade 0, in which HD brains show no gross orUniversity College London
generalized microscopic abnormalities consistent withGower Street
HD, despite premortem symptomatology and positiveLondon WC1E 6BT
family history, progressing to grade 4, in which the mostUnited Kingdom
extreme atrophy is observed (Vonsattel et al., 1985). All²Department of Neurology
grades exhibit a 30% reduction in the weight of HDMassachusetts General Hospital
brains, which has been shown to be associated withHarvard Medical School
20% to 30% areal reductions in cerebral cortex, whiteBoston, Massachusetts 02114
matter, hippocampus, amygdala, and thalamus (de la³Department of Psychiatry and Behavioral Sciences
Monte et al., 1988). This suggests that the shrinkage ofJohns Hopkins University
these structures occurs early in the disease processBaltimore, Maryland 21205-2183
and is not progressive. Gliosis was not readily apparent§Max Planck Institut fuÈ r Molekulare Genetik
in these structures and the neuronal density was as-Berlin (Dahlem), Germany
sessed to be normal (de la Monte et al., 1988). In con-‖Division of Medical and Molecular Genetics
trast, the progressive reduction in the cross-sectionalUMDS, Guy's Hospital
area of the caudate, putamen, and globus pallidus in-London SE1 9RT
creases to 60% in grades 3 to 4 HD brains, indicatingUnited Kingdom
that these structures progressively degenerate with pro-
longed survival. This specific progressive atrophy is as-
sociated with reactive astrocytosis (Vonsattel et al.,Summary
1985; Myers et al., 1991). Studies by Hedreen and
Folstein (1995) suggest that grade 0 brains, while dis-Huntington's disease (HD) is one of an increasing num-
playing no generalized striatal pathology, do have scat-ber of human neurodegenerative disorders caused by
tered islands of reactive astrocytes and circumscribed
a CAG/polyglutamine-repeat expansion. The mutation
neuronal cell loss that correspond to the striosomal
occurs in a gene ofunknown function that is expressed
compartments of the striatum. These are the earliestin a wide range of tissues. The molecular mechanism
pathological changes so far reported in HD and wereresponsible for the delayed onset, selective pattern of
found in individuals who had a 3- to 5-year history of
neuropathology, and cell death observed in HD has
chorea, although grade 0 pathology has been observed
not been described. We have observed that mice
after up to 13 years of chorea (Vonsattel et al., 1985;
transgenic for exon 1 of the human HD gene carrying
Myers et al., 1988).
(CAG)115 to (CAG)156 repeat expansions develop pro- The mutation underlying HD has been identified as a
nounced neuronal intranuclear inclusions, containing CAG/polyglutamine (polygln) expansion in the first exon
the proteins huntingtin and ubiquitin, prior to devel- of a gene encoding a large 350 kDa protein of unknown
oping a neurological phenotype. The appearance in function (Huntingtons Disease Collaborative Research
transgenic mice of these inclusions, followed by char- Group, 1993). The CAG repeat sizes in the normal and
acteristic morphological change within neuronal nu- expanded ranges are (CAG)6 to (CAG)39 and (CAG)35 toclei, is strikingly similar to nuclear abnormalities ob- (CAG)180 (referenced in Bates et al., 1997). The vast ma-
served in biopsy material from HD patients. jority of adult onset cases have expansions ranging from
40 to 55 units; expansions of 70 and above invariably
Introduction cause the juvenile form of the disease, and very few
cases have been described with expansions above 100.
Huntington's disease (HD) is an autosomal dominant The expression profile of huntingtin (htt) does not ac-
progressive neurodegenerative disorder (Harper, 1991). count for the characteristic pattern of neuropathology
Onset is generally in midlife but can vary from early observed in the brains of HD patients. Huntingtin has
childhood until well into old age, and the disease dura- been identified in all peripheral tissues studied and
tion is generally 15 to 20 years.The disorder is character- within the brain is found to be predominently neuronal
ized by a complex and variable set of symptoms that with no enrichment in the basal ganglia. It is present
have psychological, motor, and cognitive components. in cell bodies and dendrites and appears enriched in
The motor component of the adult form of the disease neuronal terminals, possibly associated with synaptic
can include chorea, dystonia, dysarthria, dysphagia, and vesicles or microtubules (DiFiglia et al., 1995; Gutekunst
restlessness; however, the disorder may progress to an et al., 1995; Sharp et al., 1995; Trottier et al., 1995a).
akinetic state. The juvenile form generally presents with At the ultrastructural level, immunoreactivity in cortical
neurons was detected in the matrix of the cytoplasma Parkinsonian rigidity and in some cases chorea may
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and around the membrane of synaptic vesicles (DiFiglia abrupt shuddering movements, stereotypic grooming
et al., 1995; Gutekunst et al., 1995). movements, and epileptic seizures. The body weight of
The dominant mechanism by which the polygln the R6/2 males decreases steadily from 8 weeks, such
expansion causes neurodegenerative disease is un- that at 12 weeks transgenic males weigh approximately
known. The mutation does not shut down transcription 60% of littermate controls. The R6/2 mice are reproduc-
or translation of the HD gene (Ide et al., 1995; Jou and tively compromised and show urinary incontinence, of
Myers, 1995; Schilling et al., 1995; Trottier et al., 1995a), which the cause, as in HD patients, is unknown. The
as mutant htt can be detected on Western blots of pro- mice appear to model many features of HD, particularly
tein isolated from both brain and peripheral tissues. In those of the juvenile variant. At 12 weeks, the only differ-
addition, a dominant negative pathway has been ruled ence between the transgenes and controls on neuro-
out by the generation of mouse knockouts in which the pathological analysis was that the brains weighed z20%
nullizygous mice have an embryonic lethal phenotype less than the normal littermate controls. The reduction
(Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995). in size was constant throughout all CNS structures,
A gain-of-function mechanism has been supported by which had an apparently normal neuronal density.
the identification of an antibody that specifically detects In this report, we have extended the neuropathologi-
pathogenic polygln expansions (Trottier et al., 1995b), cal study to include immunocytochemical analysis with
suggestive of a change in conformation occurring upon a number of antibodies raised against the N terminus
a certain size threshold, possibly facilitating novel inter- of the htt protein. In transgenic mice prior to the onset
actions. However, the molecular events by which a po- of symptoms and in control mice, the transgene shows
lygln expansion causes cell death remain to be un- a diffuse cytoplasmic staining as previously reported
raveled. for htt in rat, primate, and human brain (DiFiglia et al.,
CAG/polygln expansion has been found to form the 1995; Gutekunst et al., 1995; Sharp et al., 1995; Trottier
molecular basis for seven neurodegenerative disorders. et al., 1995a). We have identified a nuclear localization
In addition to HD, the mutated gene has been identified of the transgene protein that correlates with symptom-
for spinal and bulbar muscular atrophy (SBMA), denta- atology in each of the R6/1, R6/2, and R6/5 lines. At the
torubral pallidoluysian atrophy (DRPLA), and spinocere- ultrastructural level, this appears as a neuronal intra-
bellar ataxia (SCA) types 1, 2, 3, and 6 (referenced in nuclear inclusion (NII), and associated nuclear changes
Bates et al., 1997). The normal and expanded repeat include invaginations of the nuclear membrane and an
ranges are broadly comparable, suggesting a patho- increase in the nuclear pore density.
genic threshold in the length of the polygln tract oc-
curring at approximately 37 to 40 residues. It is likely
that a similar gain-of-function mechanism is applicable Results
to all of these diseases (except in the case of SCA6, for
which the expanded alleles are smaller and the mutation Transgene Expression in the R6 and HDex Lines
is likely to act by a different route). The proteins harbor- Expression analysis of the R6 transgenes using RT-PCR
ing the polygln stretches are mostly novel and otherwise and Northern and Western analysis was described in
unrelated but in all cases are widely or ubiquitously our initial report (Mangiarini et al., 1996). Lines R6/1,
expressed. Despite extensively overlapping expression R6/2, and R6/5 showed ubiquitous expression by RT-
patterns, the neuronal cell death is relatively specific PCR in a panel of 18 brain regions and somatic tissues,
and can differ markedly (Ross, 1995), although in the and a transcript was detected on a Northern blot for
juvenile forms of these diseases the neuropathology each of these lines. Western analysis was carried out
becomes more widespread and lessdistinct. The factors
using the 1C2 antibody (Trottier et al., 1995b), which
that convey the specific patterns of neurodegeneration
specifically recognizes pathogenic polygln expansions.
are not understood.
Using this antibody we initially did not detect a protein
We have recently generated lines of mice (R6) that
product in line R6/1, although the transgene protein wasare transgenic for the HD mutation (Mangiarini et al.,
readily detectable in lines R6/2 and R6/5. As all three1996). The transgene contains z1 kb of the human
of these lines develop a phenotype, one possible inter-HD promoter region, exon 1 carrying CAG-repeat ex-
pretation of this result is that the mutation is acting atpansions of 115 to 156 units, and 262 bp of intron 1.
the RNA rather than the protein level. However, we haveThree lines, R6/1, (CAG)115; R6/2, (CAG)145; and R6/5,
since been able to detect the transgene protein in line(CAG)128±156, develop a progressive neurological pheno-
R6/1 using three different N-terminal antibodies: AB78,type. A phenotype has not been observed in a fourth
HD1, and CAG53b, illustrated in Figure 1. The size differ-line (R6/0) in which the transgene is not expressed nor
ence observed in the transgene proteins corresponds toin two further lines transgenic for the same construct
the length of the polygln tract. As previously described,carrying 18 repeats (HDex6 and HDex27). Line R6/2 has
proteins containing polyglns migrate comparativelybeen characterized most extensively. The mice carry
slowly through SDS-PAGE gels (Aronin et al., 1995).repeat expansions ranging from 141 to 157 repeats, the
We can now also demonstrate the presence of thevariability having arisen from germ line instability (Man-
transgene protein product in the HDex control lines (18giarini et al., 1997). They exhibit a progressive, complex
CAG repeats), and it is clear that a much lower level ofneurological phenotype with an age of onset of approxi-
expression is present in line HDex6 as compared to themately 2 months. The progression of the disease is rapid
other lines. No evidence of expression at the RNA orand the mice deteriorate over the following month. The
movement disorder includes a resting tremor, rapid, protein level was detected in line R6/0.
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that exhibit a neurological phenotype (6/2 and 6/1 hemi-
zygotes, and 6/1 and 6/5 homozygotes, Figures 2E and
2F), but not in those that remain symptom free (6/0, 6/5,
HDex6, HDex27, Figure 2D). We have observed many
of these inclusions within neurons in the cerebral cortex,
striatum, cerebellum, and the spinal cord, whereas areas
such as the hippocampus, thalamus, globus pallidus,
and substantia nigra contain many fewer neurons con-
taining NII. We are currently undertaking a thorough
mapping of the distribution of NII within all the trangenic
lines. In semithin, toluidine blue±counterstained sec-
tions an htt-immunoreactive inclusion was seen in
z20% of neurons. At the ultrastructural level, reactionFigure 1. Expression of the Transgene Protein in the CNS of the R6
and Hdex Lines product was found to be densely accumulated within a
Western blot of whole brain homogenates immunostained with anti- single defined region of the nucleus that is quite distinct
body CAG53b. Transgene protein is detected in lines R6/1, R6/2, from the nucleolus, accessory body of Cajal (coiled
R6/5, Hdex6, and Hdex27. The difference in the migration of the body), or the sex chromatin (Barr bodies) found in female
proteins reflects the size of the polyglutamine tract in each case. mice (Figures 3A and 3B). Occasionally, reaction prod-
The sample in lane R6/5 is derived from an R6/5 homozygote and
uct was observed traversing pores in the nuclear mem-the observation of two protein bands results from the presence of
brane, which we interpret to be cytoplasmic htt enteringdifferent sized CAG expansions at the two R6/5 loci.
the nucleus. A dense accumulation of reaction product
was also found in multivesicular bodies present in theHuntingtin Immunoreactivity
cytoplasm of neurons that appear to be more frequentImmunohistochemical analysis of htt in the control adult
in the transgenic animals.mouse brain showed labeling of the entire gray matter,
with neuronal labeling found in all regions including the
Nuclear Morphologycerebral cortex, striatum, cerebellum, and spinal cord.
Ultrastructural analysis of the striatum in symptomaticReaction product appeared in the cytoplasm of neuronal
transgenic animals reveals the presence of a prominent,cell bodies and could also be detected in dendrites
solitary NII that appears as a roughly circular pale struc-and axons traversing the neuropil. A similar pattern of
ture easily identified in toluidine blue±stained semithinlabeling was found with three different antibodies and
sections. In thin sections, the paler dense NII is readilyis consistent with previous reports of htt distribution in
distinguished from the more darkly stained surroundingthe primate and rodent brain using the same antisera
heterochromatin (Figure 4). There is no membrane sepa-(DiFiglia et al., 1995; Sharp et al., 1995; Bhide et al.,
rating the inclusion from the surrounding nuclear matrix.1996). At the ultrastructural level, reaction product was
The structure of the NII appears to be of a fine granularscattered throughout thecytoplasm and associated with
nature with occasional filamentous structures. Thesevesicular membranes. Small patches of labeling were
filamentous structures are more readily apparent in thefound in dendrites, unmyelinated axon fibers, axon ter-
periphery around the NII. We have tried using stereoim-minals, and synaptic contacts. Reaction product was
aging (68 tilt either side of vertical at magnifications ofnever found within the neuronal nucleus.
80,000 to 200,000) to describe more accurately theIn marked contrast to the patternsof immunoreactivity
structure of the NII but cannot elucidate any additionalseen in control animals, the most prominent feature of
structural detail. Clearly, if these NII do have a fibroushtt immunoreactivity in transgenic mice was the appear-
composition, the filaments are less than 1 to 5 nm inance of a densely stained circular inclusion within neu-
diameter.ronal but not glial nuclei. This staining is in addition to
We have never identified a nuclear inclusion in anthe distribution observed in control mice. Indeed, using
astrocyte, oligodendrocyte, or microglial cell in any ofnormal concentrations of all three antisera this inclusion
the 6/2 transgenic mice, nor have we seen an NII inwas overstained, and subsequent studies used lower
transgenic lines that fail to develop a phenotype (6/0,concentrations of antibody, producing less obvious
6/5 hemizygote, Hdex27, Hdex6). Morphological investi-staining of the endogenous mouse protein (compare
gation of the NII shows that it is larger than the nucleolusFigures 2A and 2C). Analysis of thionin counterstained
(NII average diameter, 1.65 6 0.05 mm; nucleolus aver-sections suggests the presence of a single htt-immuno-
age diameter, 1.16 6 0.03 mm ) and occupies 1% of thereactive nuclear inclusion in almost all striatal neurons.
nuclear volume (nucleolus occupies 0.33%; Figure 5).An antibody that recognizes extended glutamine se-
Simple calculations suggest that a single NII, 1.65 mmquences in Western blots (Trottier et al., 1995b) recog-
in diameter, present in a nucleus 7.78 mm in diameternizes the transgenic protein in these transgenic mice
will occur in 20% of sections 70 to 90 nm in thickness.(Mangiarini et al., 1996), but fails to immunostain the
This is consistent with the observation of an NII in oneinclusion using immunocytochemical methods. Anti-
in five neurons.bodies to portions of htt not present in the transgenic
In addition to the NII, striatal neurons are invariablyprotein (Gutekunst et al., 1995) fail to recognize the nu-
found to have prominent and frequent indentations ofclear localization, suggesting that the endogenous
the nuclear membrane and often an apparent increasemouse htt protein does not colocalize with the ectopic
in the clustering and number of nuclear pores. Whiletransgenic protein. This characteristic labeling of a sin-
gle, small NII was found in all lines of transgenic mice nuclear indentations can be found in striatal neurons
Cell
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Figure 2. Huntingtin and Ubiquitin Immunoreactivity in the Striatum
Photomicrographs of htt immunoreactivity (A, C±F) or ubiquitin immunoreactivity (B) in the striatum of 6/2 (A±C), Hdex27 (D), and 6/1 (E)
hemizygous mice or in 6/5 (F) homozygous mice. The section shown in (C) was incubated in antibody that had been preabsorbed with peptide
and demonstrates a complete absence of nuclear staining. The htt (A, B, E, and F) and ubiquitin (B) immunoreactive nuclear inclusions are
indicated by the small arrows; no such inclusions can be seen in the transgenic mouse with 18 glutamine repeats (Hdex27) (D). Pale areas in
each section are the myelinated fibers of the internal capsule present throughout the darker staining striatal neuropil. Scale bar represents
100 mm for (A)±(F).
(Kemp and Powell, 1971), they are infrequent, typically Ubiquitin Immunoreactivitity
Immunocytochemical localization of ubiquitin in 6/1, 6/2,occurring in 2% to 10%. However, in symptomatic
transgenic mice, we find these changes in almost all the and 6/5 homozygous mice reveals a prominent single
nuclear inclusion (Figure 2B), identical in appearance tocells investigated. Both the frequency and extent of the
nuclear invagination is so dramatically increased that that seen with antibodies to htt (compare Figures 3A
and 3C with Figures 3B and 3D). Sections analyzed fromthese changes are diagnostic for the symptomatic mice.
However, the increase in nuclear pore density is more control mice, HDex27, HDex6, or from 6/5 hemizygous
animals reveal a low level of cytoplasmic labeling withsubjective and requires careful quantitation. Morpho-
metric analysis fails to detect any significant change in no evidence of nuclear staining. When the ubiquitin im-
munoreactive nuclear inclusions are analyzed at the EMthe size of the nucleus or the nucleolus (Figure 6), or
the accessory body of Cajal (coiled body). The distribu- level, they are found to correspond to the nuclear inclu-
sion seen by previous methods. While the NII appear totion of the heterochromatin and sex chromatin in female
mice is unaltered between transgenic and control mice. contain substantial amounts of ubiquitin, the multivesic-
Intranuclear Inclusions in HD Transgenic Mouse
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Figure 3. EM Localization of Huntingtin and Ubiquitin within the Neuronal Nucleus of Transgenic Mice
Discrete deposition of DAB reaction product within the NII with antibodies to htt (A and C) and ubiquitin (B and D). A single intensely stained
inclusion is seen with both antibodies. Scale bar for (A) and (B) is 1mm and for (C) and (D) is 500 nm.
ular bodies do not, nor do we find any ubiquitin immuno- 6/1, 6/2, or 6/5 homozygous lines. We have now ana-
lyzed the temporal sequence of the appearance for thereactive reaction product in structures that normally
nuclear changes we have reported in the 6/2 line (Figurecontain htt. Antibodies to tau protein or to phosphory-
6). This is the most severely affected of the transgeniclated epitopes of tau (Tau 134, AT8, PHF-1, ALZ 50)
lines, with a reduction in brain weight at 5 weeks, pro-or to b-amyloid failed to recognize the NII. Similarly,
gressive loss of body weight by 8 weeks, and onset ofthioflavin-S staining did not recognize a b-pleated sheet
symptoms at around 2 months. From our initial observa-conformation for the protein deposits within the NII.
tions, it was not clear whether the reduction in brainBielshowsky silver staining of neuronal nuclei readily
weight at 12 weeks was a consequence of the reductionidentified the nucleolus but failed to stain NII.
in total body weight. This longitudinal investigation
clearly demonstrates that the loss in brain weight
Progression of Neuropathological Change precedes the loss in body weight (Figure 6).
The dramatic nuclear changes we have reported thus The presence of htt immunoreactivity can be detected
in neuronal nuclei within defined regions of the cerebralfar have all been observed in symptomatic mice of the
Cell
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Figure 4. Ultrastructure of the Nucleus
Examples of the NII (A and B; indicated by large arrows) found within striatal neurons that have many indentations in the nuclear membrane
(small arrows) demonstrated with conventional electron microscopy (osmium/uranyl/lead staining). Typically, more than 90% of neurons within
the mouse striatum have a smooth nuclear profile, and all lack any inclusion (C). At higher magnifications, the NII is seen to be a pale staining
structure quite distinct from the more darkly stained adjacent nucleolus (Nu) and surrounding chromatin. Scale bar for (A)±(C) is 2 mm and
for (D) is 200 nm.
cortex beginning at 3.5 weeks and within the striatum neurons. The largest inclusions can be found within the
cerebral cortex, striatum, cerebellum (Purkinje cells),at 4.5 weeks. These NII become ubiquitinated by 5 to 6
weeks and can be detected by ultrastructural analysis and the spinal cord (motor neurons). Interestingly, within
the striatum inclusions are found in the vast majorityat 8 weeks. Morphological changes within the nuclear
membrane are the latest changes to occur, first becom- of neurons but apparently not in the giant cholinergic
interneurons or in the NADPH-diaphorase-containing in-ing apparent at 10 to 12 weeks. NII appear within the
cerebral cortex before they are found in any numbers terneurons (data not shown). We do not know if the
inclusions are exclusively within projection cells withinwithin the striatum, and they increase in sizeand staining
density for both htt and ubiquitin immunoreactivity. The the striatum or if some interneurons contain these struc-
tures. A systematic analysis is currently being performedfrequency and progressive increase in size of NII ap-
pears to vary dramatically between different classes of of the progressive appearance of NII within identified
Intranuclear Inclusions in HD Transgenic Mouse
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changes have previously been reported in EM studies
from human HD patients. The most prominent ultra-
structural change reported in biopsies of the cerebral
cortex and caudate nucleus of 18 patients with HD (Roi-
zin et al., 1979) is the presence of a nuclear inclusion
strikingly similar to those presented in this study. Other
studies report the marked change in neuronal mem-
branes, namely the increase in nuclear indentation (Roos
and Bots, 1983; Bots and Bruyn, 1987) and increase in
density of nuclear pores (Tellez-Nagel et al., 1974). It
is noteworthy that these changes were predominantly
found in biopsy material, since ultrastructural studies of
postmortem brain from patients with HD have rarely
detected similar changes (Forno and Norville, 1979).
Probably because of the great dilution of the nucleopro-
Figure 5. Morphometric Analysis of the Nucleus, Nucleolus, and NII tein, the neuronal nucleus is more difficult to preserve
Histograms of the nuclear, nucleolar, and intranuclear inclusion size for fine structural studies than are most other nuclei
for striatal neurons in control (open columns) and 6/2 transgenic
(Peters et al., 1991). More recently, immunocytochemis-mice (hatched columns). There is no significant difference between
try using Ab 1 has detected an intranuclear accumula-the size of the nucleus or nucleolus in 13-week-old 6/2 transgenic
tion of htt in the cortex and striatum of postmortem HDmice and littermate controls. The NII is significantly larger than the
nucleolus comprising 1% of the nuclear volume. brains (M. D., unpublished data).
The appearance of htt and ubiquitin within the neu-
ronal nucleus precedes any phenotypic change in the
cell types in the CNS, PNS, and nonneuronal tissues mice but is invariably linked to the subsequent develop-
during the development of the disease in line R6/2 and ment of neurological symptoms. The associated nuclear
in lines with a slower progression of phenotype. changes are likely to occur in response to this cellular
dysfunction. Throughout the symptomatic period, the
Fos B and NGFI-A Immunoreactivitity nucleus, nucleolus, accessory body of Cajal (coiled bod-
The transcription factors Fos B and NGFI-A areconstitu- ies), and sex chromatin (Barr bodies) do not change in
tively expressed in neurons throughout the mouse CNS, size or distribution between transgenic mice and lit-
and in immunocytochemical preparations neuronal nu- termate controls. The NII are not associated with the
clei are characteristically densely labeled with a promi- coiled bodies and are singular, larger structures than
nent sparing of the nucleolus. Ultrastructural analysis the more frequent (2 to 6 per cell) and smaller (0.1 to
of neuronal nuclei immunostained for either Fos B or 1.0 mm) structures termed gems (Liu and Dreyfuss,
NGFI-A in transgenic mice reveals a dense accumulation 1996). We therefore are confident that the NII identified
of reaction product throughout the nuclear matrix, with in this study are not those termed gems and implicated
a notable exclusion over the nucleolus and the NII (Fig- in neurodegeneration in spinal muscular atrophy (Liu
ure 7). In all transgenic lines that fail to develop symp- and Dreyfuss, 1996). An increase in nuclear membrane
toms, the nucleus is uniformly stained with the single indentation and the relative density of nuclear pores
exception of the nucleolus. is a feature of the neuronal response to axonal injury
(Lieberman, 1971) and is thought to reflect an increase
Discussion in communication between the cytoplasmic and nuclear
compartments of the perikaryon prior to axonal regener-
We have identified a novel molecular mechanism re- ation. Successful regeneration is however invariably ac-
sponsible for the progressive neurological dysfunction companied by an increase in nucleolar size, indicating
occurring in mice that are transgenic for the HD muta- increased protein synthesis, probably themost sensitive
tion. Neurons within the striatum of these mice contain indicator of the functional state of a neuronal cell (Lieber-
an NII that is apparent upon ultrastructural analysis and man, 1971). It seems that striatal neurons containing
contains the proteins htt and ubiquitin. This firmly estab- an NII are attempting the first stages of an ultimately
lishes a role for the expressed protein in the mechanism unsuccessful regenerative response, a situation some-
of mutation-induced disease. The NII occurs in all what reminiscent of the simultaneous dendritic regener-
transgenic lines that progress to exhibit symptoms (6/2, ation and degeneration found in Golgi impregnation of
6/1 hemizygotes and 6/1, 6/5 homozygotes) but not in neurons from postmortem human HD striatum (Grave-
asymptomatic lines (6/0, 6/5 hemizygotes, HDex6, and land et al., 1985).
HDex27), strongly implicating a causative role for the In control and presymptomatic mice, the transgene
NII in the generation of neurological dysfunction. The protein appears to have a subcellular localization con-
appearance of an NII is followed by a pronounced inden- sistent with the endogenous htt. Its translocation to the
tation of the nuclear membrane and an apparent in- nucleus occurs just prior to the onset of symptomatol-
crease in the density of nuclear pores. This increase ogy and most probably represents the dominant gain
is not confined to regions of indentation but appears of function. The molecularevents that trigger the translo-
throughout the nuclear membrane. cation to thenucleus are not clear.The transgene protein
does not itself contain a nuclear localization signal andRemarkably, all three of these ultrastructural nuclear
Cell
544
Figure 6. Progression of Pathology and Phenotype in the 6/2 Line
Timing and progression of the reduction in body weight (A) and brain weight (B) in a series of R6/2 transgenes and littermate controls. (C)
Correlation of the changes in body and brain weight with the progression of the neurological and neuropathological phenotype of 6/2 transgenic
mice.
therefore may cross the nuclear membrane by complex- C terminus of the ataxin-3 protein, containing a polygln
repeat expansion, is more toxic to COS cells in transienting with one or more cellular proteins. A number of
transfection assays that the entire ataxin-3 protein car-proteins that interact with htt have thus far been identi-
rying an identical expansion (Ikeda et al., 1996). It isfied and include HAP1 (Li et al., 1995), HIP1 (Wanker et
possible that the truncated version of htt present in theal., 1997), ubiquitin-conjugating enzyme (Kalchman et
R6 lines represents the toxic product; however, the delayal., 1996), and GAPDH (Burke et al., 1996). Immunocyto-
in the accumulation of the protein in the nucleus andchemical colocalization of htt-interacting proteins within
the onset of symptoms still indicate the necessity of aNII in the brains of symptomatic mice will be informative
threshold step.as to their possible involvement in the pathogenesis of
The polygln-containing proteins that have been foundHD. It has been suggested that polygln repeats may
to be mutated in the neurodegenerative diseases identi-form polar zippers, allowing them to interact with other
fied thus far are all widely expressed, and the factorsproteins or to homodimerize (Perutz, 1996). The obser-
that convey the specific patterns of neurodegenerationvation that recombinant protein generated from exon 1
are not understood. It may have been expected that asof the HD gene carrying (CAG)53 can form aggregates in
the R6 transgene protein contains only the N-terminalvitro may support a homodimerization model for the
3% of htt, the transgenes would represent a genericmutant protein (Scherzinger et al., 1997). Antibodies to
CAG mouse rather than a specific model of HD. The
sequences present within mouse htt but not the trans-
observed phenotype does not support this,as it displays
gene do not recognize the NII, arguing against any
many features of early onset HD and does not include an
potential interaction between the transgene and the en- overt cerebellar ataxia as described for the SCA mouse
dogenous mouse htt. htt has been shown to be specifi- models (Burright et al., 1995; Ikeda et al., 1996). We have
cally cleaved by apopain, a cysteine protease with a shown here that the appearanceof an NII containing first
key role in the proteolytic events leading to apoptosis htt and then ubiquitin immunoreactivity within certain
(Goldberg et al., 1996). It has been suggested that apo- regions of cerebral cortex followed by the striatum is
pain cleavage results in an N-terminal fragment con- consistent with the earliest neuropathological studies
taining the polygln expansion and that this truncated that identified these as the principal sites of degenera-
protein is toxic to certain cells. A mechanism of this tion in postmortem HD brain (Alzheimer, 1911). The pro-
type is supported by preliminary observations indicating nounced indentation of the nuclear membrane accom-
that it is only the N terminus of htt that is present in the panied by an increased clumping of heterochromatin is
nucleus of postmortem brains (M. D., unpublished data). suggestive of the earliest stage of apoptotic change;
however, we never detect apoptotic nuclei in either theFurther evidence is provided by the observation that the
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Figure 7. Exclusion of NGFI-A and Fos B Immunoreactivity from NII
Ultrastructural localization of the transcription factors NGFI-A (A and B) and Fos B (C and D) within the nucleus: reaction product is present
throughout the nucleoplasm but is not found overlying the nucleolus or the NII. Scale bar for (A) and (C) is 1 mm and for (B) and (D) is 500 nm.
striatum or the neocortex. It appears that these early HD-specific pattern of cellular dysfunction. The R6
transgene is under the control of endogenous promotermorphological changes do not proceed to neuronal cell
death in the R6/2 line. The localization of NII within the elements and therefore may be expected to be ex-
pressed at cellular levels comparable to endogenous htt.majority of striatal neurons but not the cholinergic or
NADPH-diaphorase-containing interneurons parallels Quantitative analysis of striatal cellular htt expression
levels in the rat (Kosinski et al., 1997) also shows anthe patterns of cell death observed in HD. The neurode-
generative process of HD appears preferentially to af- expression pattern consistent with the NII localization,
implying that the rate of formation of the NII may befect the GABA-containing projection cells prior to the
involvement of striatal interneurons (Kowall et al., 1987). largely dependent upon expression levels. This model
is supported by the observation that the NIIs appearThe cellular localization of NII in the R6/2 transgenes
therefore closely parallels the pattern of neurodegen- earlier in homozygote lines as compared to their hemizy-
gous counterparts, and that these mice have a corre-eration seen in the striatum in HD, suggesting that the
transgene is sufficient to convey at least in part an spondingly earlier age of onset and rapid progression
Cell
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Experimental Proceduresof the phenotype. Therefore, it follows that a reduction
in the level of the mutant protein may provide an avenue
Transgenic Micefor therapeutic intervention. Four lines of transgenic mice derived from a chimeric founder to-
The NII appears remarkably homogeneous through- gether with their nontransgenic littermate controls were studied (see
out its structure with the possible exception of isolated Mangiarini et al., 1996, for a full description of genotype/phenotype
of the transgenic lines used in this study). These comprised: 31 6/2fibers at the periphery. This is mirrored by an even distri-
mice and 30 controls, ranging in age from 15 days to 13 weeks andbution of the two proteins in the NII. This is in contrast
3 days; three 6/5 hemizygous (12 to 14 months) and three littermateto a recently described inclusion found predominantly
controls; five 6/5 homozygous (13 to 14 months) and three litter-
within the cytoplasm of glia in a transgenic mouse model mate controls; eight 6/1 hemizygotes (5 to 9 months) and two lit-
of amyotrophic lateral sclerosis (Bruijn et al., 1997), termate controls; one 6/1 homozygote (5 months); and one 6/0 hemi-
which has a dense central core with a lighter staining zygote (7.5 months). Ages of neurological symptoms within these
lines were approximately: 6/2 hemizygotes, 2 months; 6/1 homozy-peripheral halo. The expanded polygln tract must confer
gotes, 3 months; 6/1 hemizygotes, 5 months; and 6/5 homozygotes,a conformational change or allow molecular interactions
9 months. Additionally, two lines expressing the identical constructthat present a target for ubiquitination but do not result
carrying a (CAG)18 tract were analyzed. These were one Hdex6 (7in protein degradation. Western blot analysis of the months) and one Hdex27 mouse (4 months). Approximately seven
transgene protein has not consistently shown the pres- male R6/2 transgenes and seven littermate controls were weighed,
deeply anesthetized, and perfused at 2-week intervals from 2 to 12ence of higher molecular weight products, suggesting
weeks to allow a longitudinal study of the progression of the disor-that the protein within these structures is either dis-
der. Brains were removed and weighed postfixation. DNA was pre-rupted upon extraction or, more probably, is insoluble
pared from tail biopsy and genotyping was as previously described
in the extraction buffer. Interestingly, a high molecular (Mangiarini et al., 1996).
weight product was shown to be present in the pellet
of cell lysates prepared from COS cells transiently Tissue Processing for Light Microscopy
Animals were anesthetized with an overdose of sodium pentobarbi-transfected with the C terminus of ataxin-3 carrying
tone (Sagatal, 100 mg/kg, intraperitoneally) and perfused through(CAG)79 (Ikeda et al., 1996). This band appeared as a
the left cardiac ventricle with 35 to 50 ml of a 2% paraformaldehyde/smear, which would be consistent with ubiquitination.
lysine/periodate fixative in phosphate buffer (pH 7.4). Brains were
Only a single NII is detected in each cell, and it is never carefully removed and placed into fixative for 4 to 6 hr before being
associated with the nuclear membrane but can occur transferred to 30% sucrose in 0.1 M Tris (pH 7.4) for 48 hr at 48C.
adjacent to the nucleolus. The mechanism whereby the Brains were mounted in Tissue-Tek OCT compound (Miles Labora-
tories), frozen with powdered solid CO2, and sectioned in the coronalpresence of an NII brings about cellular dysfunction
plane at 40 mm on a sledge microtome. Sections were mountedresulting in neurological symptoms is not clear. The pale
onto gelatinized glass slides and allowed to dry overnight. Alternatestaining characteristics of the NII at the ultrastructural
sections were stained for Nissl substance with thionin before all
level are a result of the htt/ubiquitin protein precluding sections were rapidly dehydrated through ethanols, cleared in His-
the binding of transcription factors to DNA (Fos B and toclear (National Diagnostics), and coverslipped.
NGFI-A) or even heavy metals to DNA (EM studies). This
Tissue Processing for Electron Microscopymight suggest that the protein aggregate may either
Animals were anesthetized as described above and then perfuseddisplace DNA from the nuclear matrix, or it may be so
through the left cardiac ventricle with 35 to 50 ml of 4% paraformal-tightly bound to the chromatin that a protein±DNA com-
dehyde and either 0.5% glutaraldehyde or 0.1% glutaraldehyde in
plex, if formed, will not be solubilized by conventional 0.1 M Millonigs phosphate buffer (pH 7.4). The brain was removed
treatments in biochemical investigations. Irrespective of from the skull and placed in fresh fixative overnight at 48C. Coronal
sections (50 to 200 mm) were cut on an Oxford Vibratome (Lancer)the molecular mechanism of action of the NII, its pres-
and collected in serial order in 0.1 M phosphate buffer. After beingence brings about major structural changes in the nu-
osmicated (30 min in 1% OsO4 in 0.1 M phosphate buffer), thecleus, namely indentation of the nuclear membrane and
sections were stained for 15 min in 0.1% uranyl acetate in sodium
an increase in the nuclear pore density. It is strikingly acetate buffer at 48C, dehydrated in ethanols, cleared in propylene
apparent that the presence of the NII can bring about oxide, and embedded in Araldite between two sheets of Melanex
(ICI). Semithin (1 mm)sections were cut with glass knives and stainedpronounced neurological dysfunction in the absence of
with toluidine blue adjacent to thin sections cut with a diamondobvious cell death. These results clearly highlight the
knife on a Reichert Ultracut ultramicrotome. The sections were col-neuronal nucleus as theprimary site for cellular dysfunc-
lected on mesh grids coated with a thin formavar film, counter-
tion and suggest that changes in other organelles (e.g., stained with lead citrate, and viewed in a Jeol 1010 electron micro-
mitochondria, which appear with a normal morphology scope.
and in similar numbers to control mice) are secondary.
ImmunocytochemistryOur demonstration of a novel gain of function, ac-
Sections were incubated free-floating in primary antibodies at 48Cquired by expansion of the polygln sequence within htt,
for 72 hr prior to processing with biotinylated secondary antibodymay prove to be a common mechanism for all neurode-
(2 hr) and ABC complex (2 hr, Vector Elite). All washes were in 0.1
generative diseases due to polygln repeat expansion. M Tris (pH 7.4) for light microscopy and 0.1 M sodium phosphate
For in addition to the nuclear localization of htt in HD buffer for EM. Sites of peroxidase enzyme activity were visualized
by incubating sections in diaminobenzidine (25 mg/100 ml) and H2O2brain (M. D., unpublished data), a nuclear localization
(0.003%). Sections were then processed for EM or light microscopyof the ataxin-3 protein has been identified in several
as detailed above. The antibodies used in this study that recognizeregions of the brain from a Machado-Joseph disease
both exon 1 of the human and mouse htt protein were Ab 1 (1:600;
patient (Paulsonet al.,1997). Further analysis of neurons DiFiglia et al., 1995), AB 78 (1:1000; Sharp et al., 1995), HD1, and
from bothpostmortem human brain and from transgenic CAG 53b (1:2000; E. E. W. and H. Lehrach, unpublished data ). Ab
1 and Ab 78 were raised to synthetic peptides corresponding to theanimal models will rapidly confirm this.
Intranuclear Inclusions in HD Transgenic Mouse
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first 17 amino acids of htt, while CAG 53b and HD1 were raised to Burke, J.R., Enghild, J.J., Martin, M.E., Jou, Y.-S., Myers, R.M.,
Roses, A.D., Vance, J.M., and Strittmatter, W.J. (1996). Huntingtinfusion proteins. All three antisera recognized the NII in sections
and DRPLA proteins selectively interact with the enzyme GAPDH.prepared for both light and electron microscopy. The NII was un-
Nature Med. 2, 347±350.stained in sections that were either incubated in Ab 1 preabsorbed
with peptide antigen (50 mg) or in which the primary antibody was Burright, E.N., Clark, H.B., Servadio, A., Matilla, T., Fedderson, R.M.,
omitted. The antibody to ubiquitin (Dako) was used at 1:1000 and Yunis, W.S., Duvick, L.A., Zoghbi, H.Y., and Orr, H.T. (1995). SCA1
has been extensively characterized (Lowe et al., 1989). Antibodies transgenic mice: a model for neurodegeneration caused by an ex-
to Fos B (1:5000; Ebling et al., 1996) and NGFI-A (ZIF 268, 1:2000; panded CAG trinucleotide repeat. Cell 82, 937±948.
Wisden et al., 1990) detect constitutive nuclear staining in both the de la Monte, S.M., Vonsattel, J.-P., and Richardson, E.P. (1988).
rat and mouse that is abolished by prior absorption with the peptide Morphometric demonstration of atrophic changes in the cerebral
antigen. The Fos B antibody is raised against a synthetic peptide cortex, white matter and neostriatum in Huntington's disease. J.
corresponding to the N-terminal sequence of Fos B and therefore Neuropathol. Exp. Neurol. 47, 516±525.
recognizes both Fos B and DFos B (Hollen et al., 1997). Antibodies De Rooij, K.E., Dorsman, J.C. Smoor,M.A., Den Dunnen, J.T.and Van
to tau (Tau 134, Alz 50, PHF-1, and AT8) and b-amyloid have pre- Ommen, G.-J.B. (1996). Subcellular localization of the Huntingtons
viously been described (Spillantini et al., 1990; Goedert et al., 1992). disease gene product in cell lines by immunofluorescence and bio-
chemical subcellular fractionation. Hum. Mol. Genet. 5, 1093±1099.
Protein Analysis DiFiglia, M., Sapp, E., Chase, K., Schwarcz, C., Meloni, A., Young,
Frozen brain was homogenized in 1 ml of 62.5 mM Tris (pH 6.8), C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S.A., Boyce,
2% SDS, 5% 2-mercaptoethanol, 10% glycerol, and 0.001% bromo- F.M., et al. (1995). Huntingtin is a cytoplasmic protein associated
phenol blue. Homogenates were diluted 1:1 with water, boiled for with vesicles in human and rat brain neurons. Neuron 14, 1075±1081.
10 min, spun for 25 min at high speed at 48C, and the supernatant Duyao, M.P., Auerbach, A.A., Ryan, A., Persichetti, F., Barnes, G.T.,
was transferred to a fresh tube. Twenty microliters of supernatant McNeil, S.M., Ge, P., Vonstattel, J.-P., Gusella, J.F., Joyner, A.L.,
(50 mg) was loaded onto a 10% SDS-PAGE gel. Kaleidoscope and MacDonald, M.E. (1995). Inactivation of the mouse Huntington's
prestained standards were used as size markers (Bio-Rad). Proteins disease gene homolog Hdh. Science 269, 407±410.
were transferred to PVDF membranes (Bio-Rad) that were blocked
Ebling, F.J.P., Maywood, E.S., Mehta, M., Hancock, D.C., Mc Nulty,at 48C overnight in PBS with 5% nonfat dry milk. Immunoprobing
S., De Bono, J., Bray, S.J., and Hastings, M.H. (1996). Fos B in thewith polyclonal antibody CAG53b was at 1:2000 dilution in PBS with
surrachiasmatic nucleus of the Syrian and Siberian hamster. Brain0.5% nonfat dry milk for 2 hr at room temperature. Washes were in
Res. Bull. 41, 257±268.
PBS. Detection was by use of the ECL kit (Amersham).
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